Results 31 to 40 of about 720,196 (232)

Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis

Methodist DeBakey Cardiovascular Journal, 2022
Cardiac amyloidosis is increasingly recognized as an underlying cause of left ventricular wall thickening, heart failure, and arrhythmia with variable clinical presentation.
Sajan S. Gill, Eric Fellin, Lisa Stampke, Yuanzi Zhao, Ahmad Masri   +4 more
doaj   +1 more source

Cardiac Amyloidosis Treatment

Methodist DeBakey Cardiovascular Journal, 2022
Cardiac amyloidosis (CA) is a restrictive cardiomyopathy with a traditionally poor prognosis. Until recently, CA treatment options were limited and consisted predominantly of managing symptoms and disease-related complications. However, the last decade has seen significant advances in disease-modifying therapies, increased awareness of CA, and improved
Lily K. Stern, Jignesh Patel
openaire   +3 more sources

Molecular Mechanisms of Cardiac Amyloidosis [PDF]

, 2021
Cardiac involvement has a profound effect on the prognosis of patients with systemic amyloidosis. Therapeutic methods for suppressing the production of causative proteins have been developed for ATTR amyloidosis and AL amyloidosis, which show cardiac ...
Nakamura, Kazufumi, Saito, Yukihiro, Hiroshi Ito, Kazufumi Nakamura, Yukihiro Saito, Ito, Hiroshi   +5 more
core   +2 more sources

Renal AA-amyloidosis in intravenous drug users - a role for HIV-infection? [PDF]

, 2012
Background: Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades.
Grützmacher, Peter, Oliver Jung, Christoph Stephan, Markus Bickel, Peter Gruetzmacher, Kerstin Amann, Hans Stefan Haack, Jung, Oliver, Haack, Hans Stefan, Büttner, Maike, Stephan, Christoph, Bickel, Markus, Amann, Kerstin, Amann, Kerstin Ute, Betz, Christoph, Maike Buettner, Haack, Hans S., Christoph Betz   +17 more
core   +2 more sources

Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis

JACC. CardioOncology, 2020
Objectives: This study determined the diagnostic and prognostic usefulness of hepatocyte growth factor (HGF) in light chain and transthyretin cardiac amyloidosis.
Kathleen W. Zhang, MD, Jennifer Miao, MD, Joshua D. Mitchell, MD, Jose Alvarez-Cardona, MD, Kelsey Tomasek, BS, Yan Ru Su, MD, Mary Gordon, RN, R. Frank Cornell, MD, Daniel J. Lenihan, MD   +8 more
doaj   +1 more source

Transthyretin cardiac amyloidosis

Cardiovascular Research, 2022
AbstractTransthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and untreatable disease to a relatively prevalent condition that clinicians should consider on a
Aldostefano Porcari, Marianna Fontana, Julian D Gillmore   +2 more
openaire   +4 more sources

Rapid decline in ejection fraction and persistent elevation of troponin associated with cardiac amyloidosis

SAGE Open Medical Case Reports, 2020
Cardiac amyloidosis is an increasingly recognized cause of heart failure. It remains underdiagnosed despite a significant morbidity and mortality rate. The mean survival in patients with cardiac amyloidosis is less than 1 year in untreated primary light ...
Temidayo Abe, Eric Y Chang, Gabrielle De Allie, Taiwo Ajose, Chukwuemeka Nwokike, Nicolas Bakinde   +5 more
doaj   +1 more source

Potential clinical relevance of cardiac magnetic resonance to diagnose cardiac light chain amyloidosis.

PLoS ONE, 2022
BackgroundWhile patients with cardiac transthyretin amyloidosis are easily diagnosed with bone scintigraphy, the detection of cardiac light chain (AL) amyloidosis is challenging.
Zsofia Dohy, Liliana Szabo, Zoltan Pozsonyi, Ibolya Csecs, Attila Toth, Ferenc Imre Suhai, Csilla Czimbalmos, Andrea Szucs, Anna Reka Kiss, David Becker, Bela Merkely, Hajnalka Vago   +11 more
doaj   +1 more source

Transthyretin cardiac amyloidosis.

Medicine and pharmacy reports, 2021
Transthyretin amyloid cardiomyopathy (ATTR-CM) may be an under recognized cause of heart failure (HF). TTR amyloidosis can be inherited, caused by variants in the TTR gene (ATTRv) or by deposition of wild-type TTR protein (ATTRwt), leading to high mortality if untreated.
Tomoaia, Raluca, Beyer, Ruxandra, Manole, Simona, Chirilă, Alina, Dădârlat-Pop, Alexandra, Minciună, Ioan Alexandru, Pop, Dana   +6 more
openaire   +2 more sources

Technetium-99m pyrophosphate cardiac SPECT in endomyocardial biopsy negative cardiac amyloidosis

Radiology Case Reports, 2018
Cardiac amyloidosis is an under-appreciated cause of heart failure. Establishing a diagnosis is important because traditional heart failure treatment regimens can worsen left ventricular failure in this disease. Endomyocardial biopsy is the gold standard
Martin Krupa, MD, Rina Nguyen, BS, Jonathan Revels, DO, Lester S. Johnson, MD, PhD, FACR   +3 more
doaj   +1 more source